Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00NWT
|
|||
| Former ID |
DIB013375
|
|||
| Drug Name |
GR-213487
|
|||
| Synonyms |
GR-213487B; MB-121; Gene therapy (CFTR), GW; Gene therapy (CFTR), Valentis; MB-121:CFTR
Click to Show/Hide
|
|||
| Indication | Cystic fibrosis [ICD-11: CA25; ICD-10: E84, E84.9; ICD-9: 277] | Discontinued in Phase 2 | [1] | |
| Company |
Glaxo Wellcome plc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Chloride channel unspecific (ClC) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010993) | |||
| REF 2 | EP patent application no. 1336602, Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.